Biotech company Isofol Medical AB (Nasdaq First North Premier:ISOFOL) revealed on Tuesday the start of dosing of the first patient with metastatic colorectal cancer (mCRC) under the global Phase 3 AGENT study in Japan.
The company added that the drug candidate arfolitixorin is being evaluated in the first line of treatment of metastatic colorectal cancer (mCRC). The study is currently being conducted in the USA, Canada, Europe, Australia and now also in Japan.
According to the company, it plans to start the trial in up to 15 clinics in Japan, in addition to the 80 clinics that are already open.
Arfolitixorin is the company's proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.
This AGENT study is expected to enroll 440 metastatic mCRC patients in the first-line setting. The patients will receive either arfolitixorin or leucovorin, both in combination with 5-fluorouracil (5-FU), oxaliplatin and bevacizumab. Patients are randomized in a 1:1 ratio and the primary endpoint is overall response rate. The interim analysis is expected to start during the second half of 2020, concluded the company.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval